This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, R. L.
Right arrow Articles by the Vaccine Safety Datalink Team,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, R. L.
Right arrow Articles by the Vaccine Safety Datalink Team,
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 100 No. 5 November 1997, pp. 767-771

MMR2 Immunization at 4 to 5 Years and 10 to 12 Years of Age: A Comparison of Adverse Clinical Events After Immunization in the Vaccine Safety Datalink Project

Received Dec 17, 1996; accepted Apr 7, 1997.

Robert L. Davis*, Edgar Marcuse MDDagger , Steven Black§, Henry Shinefield§, Ben Givens*, Joan Schwalbe§, Paula Ray§, Robert S. Thompson*, Robert Chenparallel , and the Vaccine Safety Datalink Team*

From the * Group Health Cooperative, Seattle, Washington; Dagger  Children's Hospital Medical Center, Seattle, Washington; § Kaiser Permanente Vaccine Study Center, Oakland, California; and parallel  National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia.

Background.  The Advisory Committee on Immunization Practices recommends a second dose of measles, mumps, and rubella vaccine (MMR2) at age 4 to 5 years of age, whereas the American Academy of Pediatrics suggests MMR2 immunization at age 11 to 12 years of age. Because there is little information on whether the rate of adverse reactions to MMR2 immunization varies among these two age groups, we took advantage of differing immunization policies at two large HMOs to compare the frequency of clinical events after, and possibly related to, MMR2 immunization.

Methods.  Information was collected on clinical events plausibly associated to MMR immunization (seizures, pyrexia, malaise/fatigue, nervous/musculoskeletal symptoms, rash, edema, induration/ecchymoses, lymphadenopathy, thrombocytopenia, aseptic meningitis, and joint pain) in two cohorts. At three facilities at Northern California Kaiser (Oakland, CA), 8514 children received MMR2 immunization at age 4 to 6 years of age; at Group Health Cooperative (Seattle, WA) 18 036 children received MMR2 immunization at age 10 to 12 years of age. To account for age-related differences in health care use, within each HMO, clinical events in a 30-day period after immunization were compared with a 30-day period before vaccination.

Results.  Children 10 to 12 years of age were 50% more likely to have a clinical event after MMR2 immunization than in the period before immunization (odds ratio, 1.45; 95% confidence interval: 1.00,2.10). Children 4 to 6 years of age were less likely to have a visit for an event after immunization compared with the period before immunization (odds ratio, 0.64; 95% confidence interval: 0.40,1.01).

Conclusions.  These results suggest that the risk for clinical events after MMR2 immunizations is greater in the 10- to 12-year age group.

Key words: measles, mumps, and rubella vaccine, adverse reactions, second dose, dose schedule.




This article has been cited by other articles:


Home page
 PediatricsHome page
C. W. LeBaron, D. Bi, B. J. Sullivan, C. Beck, and P. Gargiullo
Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine
Pediatrics, October 1, 2006; 118(4): 1422 - 1430.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
L. S. Nield and D. Kamat
Lymphadenopathy in Children: When and How to Evaluate
Clinical Pediatrics, January 1, 2004; 43(1): 25 - 33.
[PDF]

Home page
 PediatricsHome page
M. Virtanen, H. Peltola, M. Paunio, and O. P. Heinonen
Day-to-Day Reactogenicity and the Healthy Vaccinee Effect of Measles-Mumps-Rubella Vaccination
Pediatrics, November 1, 2000; 106(5): 62e - 62.
[Abstract] [Full Text]

Home page
 PediatricsHome page
S. L. Katz
Harmony on the Second Dose of Measles Vaccine
Pediatrics, November 1, 1997; 100(5): 891 - 891.
[Full Text] [PDF]